Get Involved
On the day

Akeso says its closely watched drug improved patient survival in a lung cancer trial

Posted:

Akeso, a Chinese biotech with a drug positioned to rival Merck’s megablockbuster Keytruda, has reported for the first time that the therapy can improve patient survival.

Read more here.

Previous post
Back to list
Next post